Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

CONCLUSION: The efficacy of neoadjuvant chemotherapy plus nivolumab in resectable NSCLC is supported by 3-year OS. ctDNA levels were significantly associated with OS and outperformed radiologic assessments in the prediction of survival.PMID:35576508 | DOI:10.1200/JCO.21.02660

Source: Clinical Lung Cancer - May 16, 2022 Category: Cancer & Oncology Authors: Mariano Provencio Roberto Serna-Blasco Ernest Nadal Amelia Insa M Rosario Garc ía-Campelo Joaqu ín Casal Rubio Manuel D ómine Margarita Majem Delvys Rodr íguez-Abreu Alex Mart ínez-Martí Javier De Castro Carpe ño Manuel Cobo Guillermo L ópez Vivan Source Type: research